Department of Orthopedics, 307 Hospital of PLA, No. 8 East Street, Fengtai District, Beijing, 100071, China.
Clin Transl Oncol. 2013 May;15(5):370-5. doi: 10.1007/s12094-012-0933-9. Epub 2012 Sep 14.
To review the experience in transarterial neoadjuvant chemotherapy of malignant fibrous histiocytoma (MFH) in soft tissue and to analyze the factors related to prognosis of MFH in soft tissue.
Between September 1999 and December 2011, 101 cases of MFH in soft tissue patients treated by transarterial administration of Cisplatin, Adriamycin and Norcantharidin were divided into primary group and recurrent group, and the clinical documents were reviewed. Nine factors that might affect prognosis such as age, sex, tumor size, tumor site, tumor infiltration depth, recurrence if any, pathological type, histologic grade and histologic response of chemotherapy were analyzed statistically.
The 5-year relapse-free survival rate and the overall survival rate were 70.5 and 75.0 %, respectively, in the primary group; 56.1 and 57.9 %, respectively, in the recurrent group. Univariate analysis (log-rank test) showed that the factors affecting the prognosis were age (P = 0.03), tumor size (P = 0.01), pelvic tumor (P = 0.02), recurrence if any (P = 0.004), histologic grade (P = 0.01), and histologic response to chemotherapy (P = 0.007). Multivariate analysis showed that the major factors affecting prognosis were pelvic tumor (P = 0.01), tumor size (P = 0.002), histologic grade (P = 0.002), recurrence if any (P = 0.0004), and histologic response to chemotherapy (P = 0.008).
Transarterial neoadjuvant chemotherapy can significantly increase the curative efficacy of chemotherapy and survival rate in MFH treatment.
回顾软组织恶性纤维组织细胞瘤（MFH）经动脉新辅助化疗的经验，并分析软组织 MFH 预后的相关因素。
1999 年 9 月至 2011 年 12 月，101 例经动脉顺铂、阿霉素和去甲斑蝥素治疗的软组织 MFH 患者分为原发组和复发组，回顾性分析其临床资料。对可能影响预后的 9 个因素（如年龄、性别、肿瘤大小、肿瘤部位、肿瘤浸润深度、是否复发、病理类型、组织学分级和化疗组织学反应）进行统计学分析。
原发组 5 年无复发生存率和总生存率分别为 70.5%和 75.0%；复发组分别为 56.1%和 57.9%。单因素分析（log-rank 检验）显示，影响预后的因素有年龄（P=0.03）、肿瘤大小（P=0.01）、盆腔肿瘤（P=0.02）、是否复发（P=0.004）、组织学分级（P=0.01）和化疗组织学反应（P=0.007）。多因素分析显示，影响预后的主要因素有盆腔肿瘤（P=0.01）、肿瘤大小（P=0.002）、组织学分级（P=0.002）、是否复发（P=0.0004）和化疗组织学反应（P=0.008）。
经动脉新辅助化疗可显著提高 MFH 治疗的化疗疗效和生存率。
